Related Experiment Videos
Heparin-induced aldosterone suppression and hyperkalemia
J R Oster1, I Singer, L M Fishman
1Medical Service, Department of Veterans Affairs Medical Center, Miami, Florida 33125, USA.
The American Journal of Medicine
|June 1, 1995
Summary
Heparin and related compounds significantly inhibit aldosterone production, potentially leading to hyperkalemia. Clinicians should monitor serum potassium levels in patients receiving heparin for extended periods.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Aldosterone plays a crucial role in regulating electrolyte balance.
- Heparin and its analogs are widely used anticoagulants.
- Potential side effects of heparin on endocrine function require investigation.
Purpose of the Study:
- To review the effects of heparin and heparinoid compounds on aldosterone physiology.
- To examine the association between heparin use and the induction of hyperkalemia.
Main Methods:
- Comprehensive literature search of human and animal studies.
- Analysis of reference citations from primary sources.
Main Results:
- Heparin potently and specifically inhibits aldosterone production in the zona glomerulosa.
- This suppression is reversible, dose-dependent (as low as 5,000 U BID), and independent of anticoagulant activity.
- The mechanism involves reduced angiotensin-II receptor number and affinity, leading to adrenal zona glomerulosa atrophy with prolonged use.
Conclusions:
- Heparin-induced aldosterone suppression can cause natriuresis and variable potassium excretion changes.
- Hyperkalemia occurs in approximately 7% of patients, often exacerbated by renal insufficiency, diabetes, or other medications.
- Periodic serum potassium monitoring is recommended for patients on heparin for 3+ days, especially those at high risk.